<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01269762</url>
  </required_header>
  <id_info>
    <org_study_id>201001003M</org_study_id>
    <nct_id>NCT01269762</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Drug Interaction Study of Red Yeast Rice Capsules</brief_title>
  <official_title>Pharmacokinetic and Drug Interaction Study of Red Yeast Rice Capsules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Red yeast rice capsule (LipoCol Forte)is a nature product that has been demonstrated a&#xD;
      significant cholesterol lowering effect which might be caused by addictive and/or synergistic&#xD;
      effects of lovastatin (monacolin K) with other monacolins and substances in capsules. The&#xD;
      usual dose of red yeast rice capsule(LipoCol Forte)for hypercholesterolemia is one capsule&#xD;
      twice/day.&#xD;
&#xD;
      However, the pharmacokinetic profile of red yeast rice capsule (LipoCol Forte)is still&#xD;
      unknown.&#xD;
&#xD;
      The objective of the study is to evaluate the pharmacokinetic profile of red yeast rice&#xD;
      capsule (LipoCol Forte) after administering single and multiple dose to healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will divide into two groups, single and multiple doses groups. In single dose&#xD;
      group, the subjects will receive one, two and four red yeast rice capsules under fed state in&#xD;
      period one to three, respectively. In multiple doses group, the subjects will receive red&#xD;
      yeast rice capsules under fed state twice daily for 4.5 days. There is a minimum of a 5-days&#xD;
      washout period before crossover of treatments.&#xD;
&#xD;
      In single dose treatment, the blood samples will be drawn prior to the dosing, and 0.5, 1,&#xD;
      1.5, 2, 2.5, 3, 4, 6, 8 and 12 hours after the dosing.&#xD;
&#xD;
      In multiple doses treatment, the blood samples will be drawn prior to the 1st dosing, prior&#xD;
      to the 7th dosing, prior to the 8th dosing, prior to the 9th dosing, and 0.5, 1, 1.5, 2, 2.5,&#xD;
      3, 4, 6, 8 and 12 hours after the 9th dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum tolerate dosage</measure>
    <time_frame>5 weeks</time_frame>
    <description>The maxium tolerate dosage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the pharmacokinetic parameters of LipoCol Forte in healthy subjects</measure>
    <time_frame>5 weeks</time_frame>
    <description>Evaluation of pharmacokinetic parameters of LipoCol Forte in healthy subjects after single and multiple doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence rate of adverse event</measure>
    <time_frame>5 weeks</time_frame>
    <description>The incidence rate of adverse event</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>LipoCol Forte</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive single dose of one, two and four 600 milligram (mg) red yeast rice capsules (LipoCol Forte)and multiple dose of 600 mg red yeast rice Capsules (LipoCol Forte)twice daily for 4.5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LipoCol Forte</intervention_name>
    <description>Single dose of one, two and four 600 mg red yeast rice capsules (LipoCol Forte) Multiple dose of 600 mg red yeast rice Capsules (LipoCol Forte)twice daily for 4.5 days</description>
    <arm_group_label>LipoCol Forte</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must be at the age of 20-40 years old and in good health on the basis of&#xD;
             medical history, physical examination, electrocardiogram, chest X-ray, and routine&#xD;
             laboratory evaluations.&#xD;
&#xD;
          2. Vital signs (after 3 minutes resting in a upright position) which are within the&#xD;
             following ranges:&#xD;
&#xD;
             Ear body temperature between 35.0-37.5 degree celsius (Â°C). Systolic blood pressure,&#xD;
             90-140 millimeters of mercury (mm Hg). Diastolic blood pressure, 50-90 millimeters of&#xD;
             mercury (mm Hg). Pulse rate, 50-90 beats per minute (bpm). Fasting blood glucose, &lt;&#xD;
             110 milligrams per deciliter (mg/dL).&#xD;
&#xD;
          3. Body weight must be above 50 kilograms (kg) and within -20 to +20% of ideal body&#xD;
             weight.&#xD;
&#xD;
          4. Able to sign informed consent prior to study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any prescription medication within 14 days prior to dosing.&#xD;
&#xD;
          2. Use of over-the-counter medications or vitamins within 14 days prior to dosing.&#xD;
&#xD;
          3. Participation in any clinical investigation within 3 months prior to dosing or longer&#xD;
             as required by local regulation.&#xD;
&#xD;
          4. Donation or loss of more than 500 milliliter (mL) blood within 3 months prior to&#xD;
             dosing.&#xD;
&#xD;
          5. Significant illness within 2 weeks prior to dosing.&#xD;
&#xD;
          6. Presence of cardiovascular diseases.&#xD;
&#xD;
          7. Presence of gastrointestinal diseases.&#xD;
&#xD;
          8. Presence of asthma or lung diseases.&#xD;
&#xD;
          9. Presence of liver disease or liver injury.&#xD;
&#xD;
         10. Presence of impaired renal function.&#xD;
&#xD;
         11. Presence of neurological diseases.&#xD;
&#xD;
         12. Presence of psychiatrical diseases.&#xD;
&#xD;
         13. Subject is known for Human Immunodeficiency Virus (HIV) infected.&#xD;
&#xD;
         14. A known hypersensitivity to lovastatin or its analogs.&#xD;
&#xD;
         15. History of drug or alcohol abuse within 12 months prior to dosing.&#xD;
&#xD;
         16. Permanent confinement to an institution.&#xD;
&#xD;
         17. Individuals are judged by the investigator or co-investigator to be undesirable as&#xD;
             subjects for other reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Jyh-Chin, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>December 21, 2010</study_first_submitted>
  <study_first_submitted_qc>January 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2011</study_first_posted>
  <last_update_submitted>January 2, 2012</last_update_submitted>
  <last_update_submitted_qc>January 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Red yeast rice</keyword>
  <keyword>Lovastatin</keyword>
  <keyword>Drug-drug interaction</keyword>
  <keyword>Pharmacokinetics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

